Article

Mitomycin solution recalled

Mobius Therapeutics LLC is conducting a recall of two lots of mitomycin for solution 0.2 mg/vial (Mitosol Kit for Ophthalmic Use) because the affected lots may be non-sterile.

 

St. Louis, MO-Mobius Therapeutics LLC is conducting a recall of two lots of mitomycin for solution 0.2 mg/vial (Mitosol Kit for Ophthalmic Use). The company is taking this voluntary action because it cannot exclude the possibility that the affected lots may be non-sterile.

These two lots may contain a strain of yeast on one or more parts in the kit and should be considered non-sterile and unsafe for use. The affected lots are Mitosol Kit for Ophthalmic Use, NDC# 49771-002-01, Expiration date 08/2013, Lot numbers M098260 and M086920.

Mobius has initiated an investigation to determine the root cause and corrective and preventative actions.

Questions may be directed to Mobius by dialing 1-877/EYE-MITO (1/877-393-6486) and pressing option “2” Monday to Friday, 8:00 a.m. to 5:00 p.m. CST. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.